Working to make a difference in the lives of all affected by cancer.
Learn About Our Work
Explore immunotherapy discoveries, treatment approvals and milestones.
See Our Breakthroughs
Learn more about this revolutionary cancer treatment.
Understand the Basics
Meet the CRI scientists committed to the development of immunotherapy.
Innovative collaboration model designed to accelerate next-generation precision cancer immunotherapy through network of leading research centers and top scientists
Collaboration will leverage efficiencies in cancer research to rapidly implement novel Immuno-Oncology clinical studies
Bristol-Myers Squibb is the first industry partner to join a collaboration with the Parker Institute and the Cancer Research Institute
CRI iAtlas to provide immune bioinformatics tool that aims to improve cancer immunotherapy research and drug effectiveness.
The two nonprofits partnered to support four scientists whose research is focused on developing immunotherapies for patients with fibrolamellar hepatocellular carcinoma.
Researchers at 30 organizations to test algorithms that predict tumor markers from DNA in hunt for new personalized cancer treatments.
Help CRI win the $1 million grand prize.
National Headquarters | One Exchange Plaza
55 Broadway, Suite 1802 | New York, NY 10006
(800) 992-2623(212) 832-9376Staff Directory
Pembrolizumab is second anti-PD-1 drug approved for adults with cHL, first for any childhood cancer
March is Colorectal Cancer Awareness Month, and the need for a spotlight on this disease is as urgent as ever.